How is acute myeloid leukemia (AML) with genetic markers for poor-risk disease treated?

Updated: Dec 17, 2018
  • Author: Ari VanderWalde, MD, MPH, MA, FACP; Chief Editor: Karl S Roth, MD  more...
  • Print


Patients with poor-risk disease are rarely cured with chemotherapy alone and should be offered allogeneic transplantation in first remission and/or enrolled in a clinical trial. This includes patients who have intermediate-risk disease by cytogenetics but high-risk disease by molecular diagnostics, such as FLT3 -ITD. These patients also are at high risk for a relapse following transplantation, but transplant offers them the best chance of long-term remission. In an EORTC/GIMEMA trial, these poor-risk patients underwent matched-sibling stem cell transplant and had up to 43% 4-year disease-free survival. [19]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!